Evidence map›Paper›PMID 40488628›Full record

ArticleAntimicrobial agents and chemotherapy2025

A propidium iodide-based

Emmett A Dews, José E Teixeira, Christopher D Huston, Marvin J Meyers, Peter R Hyson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Evaluating acridones as novel therapeutics for human babesiosis.Antimicrobial agents and chemotherapy · 2026
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Emmett A DewsDepartment of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, USA.
José E TeixeiraDepartment of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, USA.
Christopher D HustonDepartment of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, USA.
Marvin J MeyersDepartment of Chemistry, Saint Louis University, St. Louis, Missouri, USA.
Peter R HysonDepartment of Medicine, University of Vermont Larner College of Medicine, Burlington, Vermont, USA.ORCID 0000-0002-8810-1230

Funding

Using Dengue Controlled Human Infection Model to Identify Adaptive Immune Correlates of ProtectionP20GM125498 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Kristen Pierce · 2018 to 2026
$24.9M
NIGMS NIH HHS P20 GM125498
6 · The paper itself

Abstract

The incidence and endemic range of human babesiosis are expanding. Standard therapy for human babesiosis consists of antimicrobials developed for other indications. While these treatments are adequate in immunocompetent hosts, infections in the immunocompromised can be severe, relapsing, and drug-resistant despite the use of multi-drug regimens. Existing drugs are ineffective in the immunocompromised because they cannot achieve and maintain adequate serum concentrations to inhibit

Indexed as

Antiprotozoal AgentsBabesiaPropidiumAnimalsBabesiosisDrug Evaluation, PreclinicalHigh-Throughput Screening AssaysHumansParasitic Sensitivity TestsAntiprotozoal AgentsPropidiumBabesia duncanibabesiosisdrug discoverydrug screening assayhistone deacetylase inhibitors

Identifiers

PMID40488628
PMCPMC12217462

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.